Endothelial testing market VENDYS offers a unique, FDA-cleared office-based test for vascular reactivity and endothelial dysfunction, presenting a strong value proposition to cardiology practices, primary care clinics, and preventive medicine programs seeking non-invasive, rapid risk stratification tools.

Reimbursement advantage The test is reimbursable under Medicare and private payers, enabling sales conversations focused on reimbursement pathways and favorable total cost of ownership for clinics expanding preventative screening and patient engagement programs.

Small team leverage With a lean team, VENDYS can scale through strategic partnerships, OEM-like collaborations, and pilot deployments in larger medical systems, leveraging a nimble sales approach and fast onboarding of new clients.

Clinical impact storytelling The immediate, colorful VRI reports and patient motivation aspects create opportunities to partner with primary care, cardiology, and wellness programs focused on adherence, lifestyle modification, and measurable cardiometabolic outcomes.

Tech-enabled expansion The current tech stack and cloud-enabled reporting can support integrations with EHRs and analytics platforms, enabling CMS-friendly data exchange and scalable remote monitoring opportunities across hospitals, clinics, and bundled care models.